Insulet uses new CFO Flavia Pease, as high demand for its Omnipod medical device results in an increase in revenue prospects.

Insulet, a medical device manufacturer, has its new chief financial officer, Flavia Pease, who is a former management executive at Charles River Laboratories, joining the company on September 30. She replaces Ana Maria Chadwick who will become a senior advisor.

Pease is a veteran with more than 20 years at Johnson & Johnson and provides a wide range of experience in both pharmaceutical and medical device segments. Analysts consider her appointment to be a good fit, given that she served on the board and audit committee of Insulet previously.

The firm also increased its expectations, as it projected that its revenues would increase higher in the third quarter than its earlier expectations of 22–25% due to the high demand for its wearable insulin pumps. Its Omnipod 5 medical device, which is a type 1 and type 2 diabetes device that was cleared last year, is still rolling in the U.S. and other markets.

On the basis of LSEG data, analysts expect third-quarter revenue to rise 24.47 to $677.02 million. Insulet will offer a complete report on performance and its future perspective in the November 6 earnings call.

In the meantime, Charles River Laboratories has been in the process of finding a successor to Pease, for which chief accounting officer Michael Knell will be acting as interim CFO.